IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
scle ro sis, scleroderma, restenosis and fi bro sis. It is un der go ing eval u a tion in a Eu ro pean/Ca na dian phase
II trial in pa tients with re laps ing-re mit ting mul ti ple scle ro sis and a US phase II trial in pa tients at risk for
atherosclerotic car dio vas cu lar dis ease as well as pre clin i cal stud ies in the USA for the treatment of
scleroderma with Millennium (now Takeda).
MLN 518 (tandutnib), an in hib i tor of the FLT3 re cep tor ty ro sine kinase (RTK), as an orally de liv ered ther -
apy with po ten tial in the treat ment of acute myelogenous leu ke mia (AML) and glioblastoma was in phase
II tri als in the US in 2009 with Mil len nium (now Takeda).
MLN 4924 is a small mol e cule in hib i tor of the Nedd 8 ac ti vat ing en zyme (NAE) which con trols a sub set of
pro teins in the ubiquitin proteaseome path way that reg u late can cer cell sur vival. It was un der go ing two
phase I dose es ca la tion tri als with Mil len nium (now Takeda) in the US in 2009.
MLN 8054, an orally act ing, small mol e cule au rora A kinase in hib i tor for the po ten tial treat ment of ad -
vanced ma lig nan cies is un der go ing US phase I eval u a tion in pa tients with a range of solid and he ma to -
log i cal tu mors with Mil len nium (now Takeda) in 2009.
MLN 8054, an orally act ing, small mol e cule au rora A kinase in hib i tor for the po ten tial treat ment of ad -
vanced ma lig nan cies is un der go ing US phase I eval u a tion in pa tients with a range of solid and he ma to -
log i cal tu mors with Mil len nium (now Takeda) in 2009.
MLN 2238, a sec ond-gen er a tion proteasome in hib i tor, for the po ten tial treat ment of can cer was un der -
go ing pre clin i cal eval u a tion in 2008 with Mil len nium (now Takeda).
AMG 655, a fully hu man monoclonal agonistic an ti body tar get ing the extracellular do main of the hu man
TNF-re lated apoptosis-in duc ing ligand (TRAIL) re cep tor 2 (TR-2), for the po ten tial treat ment of can cer
was in phase 1 de vel op ment with Takeda in Ja pan in 2009. In Feb ru ary 2008 Amgen and Takeda signed
an agree ment un der which Takeda will de velop and com mer cial ize in Ja pan up to 13 of Amgen’s early- to
mid clin i cal-stage can di dates, in clud ing AMG 655. It is un der go ing phase II tri als in the US in the treat -
ment of solid tumors and lymphomas with Amgen.
TAK 285, an oral HER2 in hib i tor was in a phase I trial for solid tu mors with Takeda in 2009; pre clin i cal re -
sults have been re ported.
TAK 700, an oral sex hor mone syn the sis in hib i tor was re ported to be in phase I tri als for pros tate can cer
with Takeda in 2009.
TAK 448, a go nad o tro pin-re leas ing hor mone (GnRH) mod u la tor for the po ten tial treat ment of pros tate
can cer, that re duces tes tos ter one lev els rap idly and strongly is un der go ing phase I eval u a tion in Japan in
2009.
TAK 593, an oral in hib i tor of the ty ro sine kin ases for the VEGFR and PDGFR fam i lies, was un der go ing
phase I eval u a tion in Ja pan for the po ten tial treat ment of solid tumors in 2009.
AMG 386, an angiopoietin (ANG) re cep tor an tag o nist, is in phase II stud ies with Amgen for the po ten tial
treat ment of solid tu mors. In Feb ru ary 2008 Amgen and Takeda signed an agree ment un der which
Takeda will de velop and com mer cial ize in Ja pan up to 13 of Amgen’s early- to mid clin i cal-stage can di -
dates, including AMG 386.
HUL 2G7, a monoclonal an ti body with po ten tial in the treat ment of brain tu mors in clud ing gliomas. HuL
2G7 is de signed to in hibit hepatocyte growth fac tor (HGF), which is in volved in tu mor cell di vi sion, tu mor
angiogenesis and tu mor cell re sis tance to che mo ther apy and ra di a tion. The monoclonal is un der go ing
pre clin i cal eval u a tion in the USA. Gal axy (USA) an tic i pates com menc ing clin i cal tri als in 2007 and in 2008
Takeda con firmed that prep a ra tion for clinical trials is ongoing.
© 2009 IMS Health In cor po rated or its af fil i ates Page 68